Electrophysiology Catheters Market Size to Grow by USD 2.24 Billion from 2022-2027

Abbott Laboratories, Acutus Medical Inc., and Johnson and Johnson are some of the major companies in the market - Technavio

The Electrophysiology Catheters Market size is expected to grow by USD 2.24 billion, accelerating at a CAGR of 8.73% during the forecast period, according to Technavio Research. Companies are implementing various strategies like forming partnerships, mergers, expanding into new areas, and launching new products to improve their market position. The report also offers detailed analyses of the market’s competitive landscape, featuring information on leading companies including Abbott Laboratories, Acutus Medical Inc., AngioDynamics Inc., APT Medical, AtriCure Inc., BIOTRONIK SE and Co. KG, Boston Scientific Corp., CardioFocus Inc., CathRx Pty Ltd., Japan Lifeline Co. Ltd., Johnson and Johnson, Koninklijke Philips N.V., Medtronic Plc, Merit Medical Systems Inc., MicroPort Scientific Corp., Millar Inc., Nihon Kohden Corp., OSYPKA AG, Siemens Healthineers AG, Stereotaxis Inc. and Stryker Corp. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment.

Electrophysiology Catheters Market: Company Profile

Abbott Laboratories: The company offers electrophysiology catheters such as Advisor HD grid sensor-enabled mapping catheter.

To gain access to more company profiles available with Technavio, buy the report

Electrophysiology Catheters Market: Segmentation Analysis

The market is segmented by End-user (Hospitals and cardiac centers and ASCs), Product (Ablation catheters and Diagnostic catheters), and Geography (North America, Europe, Asia, and Rest of World (ROW)).

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. Download the free sample report here

Electrophysiology Catheters Market: Geographical Analysis

It is projected that North America will play a substantial role, contributing approximately 38% to the global market’s growth during the forecast period. In developed nations within the region, notably the United States and Canada, the presence of well-established healthcare facilities is driving increased demand for balloon catheters and cardiac ablation catheters.

Electrophysiology Catheters Market: Driver, Trend & Challenge

Driver – The growth of the electrophysiology catheter market is driven by the increasing incidence of cardiac diseases and the expansion of insurance providers. Heart disease prevalence is rising globally, including valvular heart disease, especially due to increased life expectancy. High blood pressure is a leading cause of conditions like atrial fibrillation, which can lead to strokes or heart attacks. Additionally, healthcare options like the European Health Insurance Card (EHIC) in the EU and medical screenings provided by the UK’s National Health Service (NHS) further contribute to market growth.

Trends – The use of remote navigation in cardiac mapping and imaging is the key trend in the market.

Challenges – A stringent regulatory framework is a challenge that affects the growth of the market.

Identify more information on key trends, drivers, and challenges of the market. Download to gain access to this information

What are the key data covered in this electrophysiology catheters market report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the electrophysiology catheters market between 2022 and 2027.
  • Precise estimation of the electrophysiology catheters market size and its contribution to the market in focus on the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market across North America, Europe, Asia, and ROW
  • A thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of electrophysiology catheters market vendors.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version